AstraZeneca Still Believes in Effective Covid-19 Vaccine by End 2020

Pascal Soriot, executive director of the company responsible for the Oxford vaccine, points out that there is still no definitive diagnosis about the patient who halted clinical trials.

RIO DE JANEIRO, BRAZIL - The abrupt suspension of the coronavirus vaccine clinical trials developed by Oxford University and AstraZeneca pharmaceutical company sounded the alarm worldwide. However, Pascal Soriot, executive director of the Anglo-Swedish company, minimized the event on Thursday during a videoconference.

"It is very common, as many experts can confirm. The difference with other Subscribe to our Premium Membership Plan. Already Subscribed?